DERM — Journey Medical Corp

Journey Medical Corp (DERM) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Claude Maraoui, based in 9237 East Via de Ventura Boulevard, Scottsdale, AZ, United States, 85258, with about 41 employees. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Latest reported DERM revenue for 2025-09-30 was $17.6M. Net income was -$10.2M. Revenue was up 17.5% from 2025-06-30 to 2025-09-30. DERM currently screens at market cap $163.1M.

Use this DERM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DERM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DERM SEC filings page. Lician reads the product cache first so this HTML stays unique to Journey Medical Corp even when a live quote feed is slow.